British Columbia Drug and Poison Information Centre (BC DPIC)
Healthcare Professionals
Health Headlines
Weblinks
About DPIC
Contact
Index
Log in
Search this site:
Poison Information
24-Hour Line:
1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
General Information
Prevention Tips
Prevention Material
Fact Sheets
BC Poison Control
Springtime Hazards
Holiday Hazards
Poison FAQ
Antidote Stocking Guidelines
UPDATED
Opioid Guidelines
Poison Management Manual
Drug Information
Drug Information Line
for BC Healthcare Professionals Only
1-866-298-5909 or
604-707-2787
(Mon - Fri, 9am to 4pm)
Clinical Practice Guidelines
Drug Product Listings
Safe Medication Use
Adverse Reaction Reporting
DI Perspectives Newsletter
Drug Desk Newsletter
Home
›
Drug Product Listings
› Lapatinib ditosylate
Lapatinib ditosylate
Trade Name:
Tykerb
Manufacturer/Distributor:
GlaxoSmithKline
1-800-387-7374 (Medical Information); www.gsk.ca
Classification:
Antineoplastic agent
ATC Class:
L01XE07 Lapatinib
Status:
active
Notice of Compliance (yyyy/mm/dd):
2009/05/15
Date Marketed in Canada (yyyy/mm/dd):
2009/05
Presentation:
Tablet: 250 mg; DIN 02326442
Comments:
To be used in combination with capecitabine for treatment of patients with advanced or metastatic breast cancer (tumours overexpress HER2). Before starting lapatinib, patients should have already used taxanes, anthracycline and trastuzumab.
Back to:
Drug Product Listings
-
A
+
A
Follow DPIC
Facebook
Twitter
Take the DPIC Caller Satisfaction Survey